# Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

> **NCT00141024** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 84 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** EP HIV-1043
- **BIOLOGICAL:** EP HIV-1090

## Key facts

- **NCT ID:** NCT00141024
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141024, "Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00141024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*